<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310583</url>
  </required_header>
  <id_info>
    <org_study_id>2005-000411-10</org_study_id>
    <secondary_id>BfArM61-3910-4030984</secondary_id>
    <secondary_id>4478944789</secondary_id>
    <secondary_id>EV2005-2509</secondary_id>
    <nct_id>NCT00310583</nct_id>
  </id_info>
  <brief_title>Effects of Pregabalin on Mechanical Hyperalgesia</brief_title>
  <official_title>Effects of Pregabalin on Mechanical Hyperalgesia - EPOM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professional Associations Clinic Bergmannsheil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Professional Associations Clinic Bergmannsheil</source>
  <brief_summary>
    <textblock>
      The aim of this randomized placebo-controlled study is to evaluate the effects of analgetics&#xD;
      for neuropathic pain on mechanical hyperalgesia as a kind of evoked pain. Therefore the&#xD;
      number of responders and non-responders on pregabalin will be evaluated in respect of&#xD;
      mechanical hyperalgesia (stimulus-response-function (SRF) on static punctual stimuli evoking&#xD;
      pain determined via pinprick). The hypothesis is that in the placebo group the amount of&#xD;
      non-responders is increased.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized controlled trial is intended to be the first in a series of trials that will&#xD;
      assess the efficacy of drugs, which relieve neuropathic pain, on stimulus-evoked pain (here:&#xD;
      mechanical hyperalgesia to static punctate stimuli). Most drugs in this class (e.g.&#xD;
      Gabapentin or NMDA receptor inhibitors) have NNT beyond 3 in patients with chronic pain, due&#xD;
      to a response rate of 30 to 50 %. One potential reason for this low overall efficacy might be&#xD;
      the presence of different pathophysiological mechanisms in subgroups of patients, who suffer&#xD;
      from the same disease (e.g. postherpetic neuralgia, diabetic neuropathy). These mechanisms&#xD;
      may include central sensitization on one hand and peripheral degeneration of afferent fibers&#xD;
      on the other hand.&#xD;
&#xD;
      In this trial, we will use a battery of mechanical and thermal Quantitative Sensory Tests&#xD;
      (QST), using non-nociceptive and low-intensity painful stimuli, to identify a subgroup of&#xD;
      patients with mechanical hyperalgesia. To overcome the well-known low response rate in trials&#xD;
      with neuropathic pain patients, an enriched design comparing active drugs with placebo will&#xD;
      be performed, including only patients with high intensity of on-going pain in combination&#xD;
      with mechanical hyperalgesia as sequelae of different, but well defined neurological&#xD;
      disorders. The blinded phase of the trial will be restricted to so-called responders, i.e.&#xD;
      patients with a clinically meaningful pain reduction of at least 30% in the primary end point&#xD;
      (mechanical hyperalgesia). The second objective of this trial is to evaluate, whether the&#xD;
      anti-hyperalgesic effect of the active drug is dependent on the QST profile.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">April 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of responders and non-responders in respect of mechanical hyperalgesia (stimulus-response-function (SRF) on static punctual stimuli evoking pain determined via pinprick)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of mechanical hyperalgesia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pain (numerical rating scale)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathic Pain Symptom Inventory score</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable CDT = cold detection threshold,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable HDT = heat detection threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable TSL = thermal sensory limen</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable PHS = number of paradoxical heat sensations during the TSL Procedure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable CPT = cold pain threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable HPT = heat pain threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable MDT = mechanical detection threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable MPT = mechanical pain threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable ALL = dynamic mechanical allodynia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable WUR = windup ratio</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable VDT = vibration detection threshold</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional QST (qualitative sensory testing) variable PPT = pressure pain threshold)</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Tactile Hyperalgesia</condition>
  <condition>Neuropathic Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Recruitment:&#xD;
&#xD;
          -  Age above 18 years;&#xD;
&#xD;
          -  Neuropathic pain of at least 4/10 for at least 6 months;&#xD;
&#xD;
          -  Mechanical hyperalgesia;&#xD;
&#xD;
          -  One of the following diagnoses: peripheral nerve lesion, plexus lesion, radicular&#xD;
             lesion, spinal lesion, polyneuropathy, postzosteric neuralgia;&#xD;
&#xD;
          -  No nerve block or other interventional treatment for at least 4 weeks;&#xD;
&#xD;
          -  Constant medication for at least 4 weeks;&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
          -  WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L&#xD;
             or equivalent units of HCG) within 72 hours prior to the start of study medication;&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must be using an adequate method of&#xD;
             contraception to avoid pregnancy throughout the study and for up to 4 weeks after the&#xD;
             study in such a manner that the risk of pregnancy is minimized.&#xD;
&#xD;
        Enrolment open titration:&#xD;
&#xD;
          -  All principal inclusion criteria at recruitment&#xD;
&#xD;
          -  Relevant mechanical hyperalgesia: SRF affected/control at least 2.0 with a minimal SRF&#xD;
             of 0.8.&#xD;
&#xD;
        Enrolment double-blind phase:&#xD;
&#xD;
          -  At least 30% reduction in mechanical hyperalgesia (SRF) in the open titration;&#xD;
&#xD;
          -  WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L&#xD;
             or equivalent units of HCG) within 72 hours prior to the start of study medication;&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must be using an adequate method of&#xD;
             contraception to avoid pregnancy throughout the study and for up to 4 weeks after the&#xD;
             study (see above recruitment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anaphylaxis on the active component or any other component of Lyrica or the placebo&#xD;
             (LyricaÂ®: pregabalin, lactose-monohydrate, corn starch, talcum; capsule shells:&#xD;
             gelatine, titanium dioxide (E 171), natriumdodecylsulfat, high dispersive&#xD;
             siliciumdioxide, purified water; ink: shellac, black iron(II,III)-oxide (E 172),&#xD;
             propyleneglycol, kaliumhydroxide; additionally in placebo: microcrystalline cellulose,&#xD;
             sucrose octaacetate, magnesium stearate)&#xD;
&#xD;
          -  Intake of gabapentin or pregabalin within the last 4 weeks prior to recruitment&#xD;
&#xD;
          -  Any surgery within the last two months or any scheduled surgery within the study&#xD;
             period (20 weeks);&#xD;
&#xD;
          -  Concurrent unstable disease involving any system, e.g. advanced carcinoma, acute&#xD;
             myocardial infarction, renal failure, or any other condition that in the opinion of&#xD;
             the Investigator would deem the patient unsuitable for the study;&#xD;
&#xD;
          -  History of cerebral vascular or other cerebral disease;&#xD;
&#xD;
          -  Concurrent chronic or acute pain of other origin (osteoarthritis), which is not&#xD;
             treated effectively&#xD;
&#xD;
          -  Concurrent severe mental deficit, e.g. psychiatric disorders as defined by DSM IV&#xD;
             including schizophrenia, mood disorders, organic brain syndrome, psychotic/delusional&#xD;
             disorders, serious psychosis;&#xD;
&#xD;
          -  Concurrent serious neurological disease, e.g. dementia, multiple sclerosis, or any&#xD;
             other disease that would have impact on the ability of the patient to give their&#xD;
             consent for the participation in the study or influences the pain perception;&#xD;
&#xD;
          -  Concurrent atrioventricular block second degree or higher&#xD;
&#xD;
          -  Concurrent renal failure (CLcr &lt; 30 ml/min)&#xD;
&#xD;
          -  Concurrent hereditary galactose-intolerance&#xD;
&#xD;
          -  Concurrent lapp-lactase insufficiency&#xD;
&#xD;
          -  Concurrent glucose-galactose-malabsorption&#xD;
&#xD;
          -  Concurrent sub-optimal stabilized Diabetes Mellitus (Hb1Ac &gt; 12%)&#xD;
&#xD;
          -  Clinical apparent overdosage of opioids or psychopharmaca&#xD;
&#xD;
          -  Recent history (6 months) or current evidence of alcohol or drug abuse;&#xD;
&#xD;
          -  Participation in any other investigational drug or therapy study within the previous&#xD;
             90 days;&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding;&#xD;
&#xD;
          -  Women with a positive pregnancy test on enrollment or prior to study drug&#xD;
             administration;&#xD;
&#xD;
          -  Women of childbearing potential who are unwilling or unable to use an acceptable&#xD;
             method to avoid pregnancy for the entire study period and for up to 4 weeks after the&#xD;
             study. Women practicing abstinence should use a reliable method of contraception&#xD;
             (except birth control pills) if they choose to become sexually active during the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Maier, Prof. MD.</last_name>
    <role>Study Director</role>
    <affiliation>Professional Associations Clinic Bergmannsheil , Dept. of Pain Therapy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christoph Maier, Prof. MD</last_name>
    <phone>+49 (0)234 - 302 - 6366</phone>
    <email>christoph.maier@rub.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Berufsgenossenschaftliche Kliniken Bergmannsheil, Dept. of Anaesthesiology, Intensive Care and Pain Therapy, Dept. of Pain Therapy</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christhop Maier, Prof. MD</last_name>
      <phone>+49(0)234-302-6366</phone>
      <email>christoph.maier@rub.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Maier, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Scherens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pain Therapy, Dept. of Anaesthesiology and Intensive Care Medicine, University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank Petzke, MD</last_name>
      <phone>+49(0)221-478-3627</phone>
      <email>frank.petzke@uni-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Thorsten Giesecke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Petzke, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Duesseldorf, Dept. of Paintherapy, Dept. of Anaesthesiology</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rainer Freynhagen, MD</last_name>
      <phone>+49(0)211-81-19157</phone>
      <email>freynhagen@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Rainer Freynhagen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Schmitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Busche, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesiology, University Hospital of Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wolfgang Koppert, PD MD</last_name>
      <phone>+49(0)9131-85-32901</phone>
      <email>koppert@kfa.imed.uni-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Koppert, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insitute of Physiology and Experimental Pathophysiology</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian MaihÃ¶fner, MD</last_name>
      <phone>+49(0)9131-85-22498</phone>
      <email>christian.maihoefner@neuro.imed.uni-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Christian MaihÃ¶fner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological University Hospital, University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingolf C BÃ¶tefÃ¼r, MD</last_name>
      <phone>+49(0)761-270-5001</phone>
      <email>botefur@nz.ukl.uni-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Ingolf C BÃ¶tefÃ¼r, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neuroradiology, Neurological Health Care Center, University Hospital of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Stippich, PD MD</last_name>
      <phone>+49(0)6221-56-39607</phone>
      <email>christoph.stippich@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Stippich, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Neurological Section, Pain Research and Therapy, UniversitÃ¤tsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf Baron, Prof. MD</last_name>
      <phone>+49(0)431-597-1809</phone>
      <email>r.baron@neurologie.uni-kiel.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Baron, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Binder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janne Ludwig, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>J Schattschneider, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Care Centre, Dept. of Neurology, Johannes Gutenberg University of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Birklein, Prof. MD</last_name>
      <phone>+49(0)6131-17-3270</phone>
      <email>birklein@neurologie.klinik.uni-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Frank Birklein, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Gerber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roman Rolke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DRK - Pain Centre Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susann Seddigh, MD</last_name>
      <phone>+49(0)6131-988510</phone>
      <email>susann.seddigh@drk-schmerz-zentrum.de</email>
    </contact>
    <investigator>
      <last_name>Susann Seddigh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pain Therapy, Dept. of Anaestesiology and Intensive Care Medicine, Clinical Medicine Mannheim, University of Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrike Friess, MD</last_name>
      <phone>+49(0)621-383-2608</phone>
      <email>ulrike.friess@anaes.ma.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Ulrike Friess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anesthesiology and Surgical Intensive Care Medicine, University of Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Esther Pogatzki-Zahn, PD MD</last_name>
      <phone>+49(0)251-834-7258</phone>
      <email>pogatzki@anit.uni-muenste.de</email>
    </contact>
    <investigator>
      <last_name>Esther Pogatzki-Zahn, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interdisciplinary Dept. of Pain Management, Dept. of Anaesthesiology, Ludwig-Maximilians-University</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shanhnaz C Azad, PD MD</last_name>
      <phone>+49(0)89-7094-4464</phone>
      <email>Shahnaz.Azad@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Shanhaz C Azad, PD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meike Lauchert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Volker Huge, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Universtity Hospital TU Munich</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas R Toelle, Prof. MD</last_name>
      <phone>+49(0)89-4140-4603</phone>
      <email>toelle@neuro.med.tu-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Thomas R Toelle, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Valet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Till Sprenger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorothee Nietzsche, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Bach, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Achim Berthele, PD MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Anaesthesia and Transfusion Medicine, University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine Bredanger, MD</last_name>
      <phone>+49(0)7071-29-85612</phone>
      <email>sabine.bredanger@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Sabine Bredanger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Klaus Unertl, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard G. Landwehrmeyer, Prof. MD</last_name>
      <phone>+49(0)731-500-50950</phone>
      <email>bernhard.landwehrmeyer@uni-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Bernhard G. Landwehrmeyer, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roland Klug, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Hospital, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Sommer, Prof. MD</last_name>
      <phone>+49(0)931-201-23763</phone>
      <email>sommer@mail.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Claudia Sommer, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nurcan Uceler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.bmbf.de/</url>
    <description>German Ministry of Education and Research</description>
  </link>
  <link>
    <url>http://www.bfarm.de</url>
    <description>German Federal Institute for Drugs and Medical Devices</description>
  </link>
  <link>
    <url>http://www.ruhr-uni-bochum.de/ethik/</url>
    <description>Ethics Committee, Medical Department of the Ruhr-University Bochum</description>
  </link>
  <verification_date>April 2006</verification_date>
  <study_first_submitted>April 3, 2006</study_first_submitted>
  <study_first_submitted_qc>April 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2006</study_first_posted>
  <last_update_submitted>April 4, 2007</last_update_submitted>
  <last_update_submitted_qc>April 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2007</last_update_posted>
  <keyword>tactile hyperalgesia</keyword>
  <keyword>neuropathic pain</keyword>
  <keyword>enriched design</keyword>
  <keyword>peripheral nerve lesion</keyword>
  <keyword>plexus lesion</keyword>
  <keyword>radicular lesion</keyword>
  <keyword>spinal lesion</keyword>
  <keyword>polyneuropathy</keyword>
  <keyword>postzosteric neuralgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

